Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Oxford BioDynamics
Oxford BioDynamics
X
LinkedIn
Trending Articles
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Actylis and Novo Nordisk Pharmatech partner for the distribution of benzalkonium chloride
The two companies aim to expand the distribution of benzalkonium chloride within Europe
Upperton opens novel development and GMP manufacturing facility
The novel 50,000 sqft development and GMP manufacturing facility in Nottingham contains ten GMP manufacturing suites, quality control laboratories and formulation development...
Astellas begins construction of manufacturing site in Tralee
600 construction jobs and 100 specialised engineering, science and technology roles will be created from the project
Policy vacuum risks UK becoming a medicines supply backwater
The UK becoming a "backwater" supply marker could jeopardise £18bn of NHS savings from newly off-patented drugs during the next five years
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Pharmaceutical
Oxford BioDynamics appoints professor to its Scientific Advisory Board
Professor Iain McInnes will apply his expertise and insight as the company’s EpiSwitch technology continues to be adopted
Pharmaceutical
Oxford BioDynamics appoints new President for US subsidiary
Glen Ferguson has been made Senior VP of US at the parent company, but has also been appointed as the President of the new US subsidiary
Finance
Oxford BioDynamics signs fifth collaboration agreement in immuno-oncology space
The company will use its EpiSwitch platform to offer high resolution mapping of epigenetic profiles in patients
Pharmaceutical
Grant announcement of Canadian patent by Oxford BioDynamics
The now patented technology platform, EpiSwitch, enables the high resolution discovery and monitoring of regulatory conditional chromosome conformation signatures
Research & Development
OBD presents latest data on the use of EpiSwitch
EpiSwitch biomarkers have the potential to predict patient response to treatments with immune checkpoint inhibitors anti-PD-1 and anti-PD-L1
Research & Development
Collaboration identifies tool to predict response to rheumatoid arthritis therapy
Study published in Journal of <i>Translational Medicine</i> demonstrates predictive power of EpiSwitch to identify inadequate response to methotrexate in early rheumatoid arthritis
Pharmaceutical
Oxford BioDynamics appoint Paul Stockdale CFO
Subscribe now